Literature DB >> 29930715

Leinal polypeptide promotes NK cells to suppress PCa survival in vitro.

Qun Rao1, Huiping Zhang2, Cuantai Zhang3, Qianyuan Zhuang4, Guanghui Du4, Shaogang Wang4, Zhangqun Ye4, Yuan Chen3,4.   

Abstract

As an important component in the innate immune system, natural killer (NK) cells have been demonstrated to be clinically associated with prostate cancer (PCa) progression and castration resistance. Therefore, the development of novel agents that may enhance the cytotoxicity of NK cells possesses promising therapeutic applications. In the present study, leinal polypeptide (LP) solution was supplemented into a co-culture system of NK and PCa cells, as it was previously demonstrated that LP are able to activate NK cells, which kill PCa cells based on an MTT cell viability assay. Mechanistic dissection demonstrated that LP enhanced androgen receptor degradation, which resulted in an upregulation of MHC class I polypeptide-related sequence A (MICA) and MICB. In turn, the induced expression of MICA and MICB was able to further trigger NK cell activation, forming a positive loop between NK cells and PCa cells in the presence of LP solution.

Entities:  

Keywords:  leinal polypeptide; natural killer cells; prostate cancer

Year:  2018        PMID: 29930715      PMCID: PMC6006496          DOI: 10.3892/ol.2018.8632

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  23 in total

Review 1.  CYP17 inhibitors for prostate cancer therapy.

Authors:  Tadas S Vasaitis; Robert D Bruno; Vincent C O Njar
Journal:  J Steroid Biochem Mol Biol       Date:  2010-11-17       Impact factor: 4.292

2.  EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE.

Authors:  C Huggins
Journal:  Ann Surg       Date:  1942-06       Impact factor: 12.969

Review 3.  Therapeutic targeting of the prostate cancer microenvironment.

Authors:  Maria Karlou; Vassiliki Tzelepi; Eleni Efstathiou
Journal:  Nat Rev Urol       Date:  2010-09       Impact factor: 14.432

4.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

5.  Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).

Authors:  Shin-Jen Lin; Fu-Ju Chou; Lei Li; Chang-Yi Lin; Shuyuan Yeh; Chawnshang Chang
Journal:  Cancer Lett       Date:  2017-03-31       Impact factor: 8.679

Review 6.  Androgen receptor in prostate cancer.

Authors:  Cynthia A Heinlein; Chawnshang Chang
Journal:  Endocr Rev       Date:  2004-04       Impact factor: 19.871

7.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

8.  The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development.

Authors:  Paul G Corn
Journal:  Cancer Manag Res       Date:  2012-07-25       Impact factor: 3.989

9.  The Wilms' tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells.

Authors:  Adina Brett; Sony Pandey; Gail Fraizer
Journal:  Mol Cancer       Date:  2013-01-08       Impact factor: 27.401

10.  Postoperative renormalization of C-reactive protein with adjuvant lienal polypeptide and its association with tumour recurrence in T1 clear cell renal cell carcinoma.

Authors:  Yijun Guo; Qingfeng Hu; Chuanyu Sun; Bin Gu; Ke Xu; Guowei Xia
Journal:  J Int Med Res       Date:  2016-03-04       Impact factor: 1.671

View more
  1 in total

1.  The effectiveness and safety of lienal polypeptide combined with chemotherapy or chemoradiotherapy for non-small cell lung cancer patients in real world.

Authors:  Zhe Wang; Junfeng Liu
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.